Anadrol and Modafinil Interaction: Avoid | Peptide Database

Join others researching Survodutide — share findings, ask questions, and learn from real experiences Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy. Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0.52nM GCGR, 0.33nM GLP-1R.

First-line pharmacotherapy for type 2 diabetes per ADA/EASD guidelines. Reduces HbA1c by 1.0-1.5% as monotherapy. Proven cardiovascular mortality reduction in the UKPDS trial. Can be used alone or in combination with other antidiabetic agents. Delays or prevents progression from prediabetes to type 2 diabetes. The Diabetes Prevention Program (DPP) showed a 31% reduction in diabetes incidence with metformin compared to placebo over 2.8 years. Particularly effective in younger, more obese individuals. Improves multiple components of metabolic syndrome including fasting glucose, insulin resistance, and visceral adiposity. Often used off-label in non-diabetic individuals with metabolic syndrome who have failed lifestyle interventions. Improves insulin resistance, reduces androgen levels, and may restore ovulatory function in women with PCOS. Used as adjunctive therapy alongside lifestyle modifications. Effectiveness varies and is most pronounced in women with significant insulin resistance. Observational studies suggest diabetic patients on metformin may have lower all-cause mortality than non-diabetic controls. The TAME trial is the first FDA-approved clinical trial to specifically target aging as an indication. Proposed mechanisms include AMPK activation, mTOR inhibition, reduced inflammation, and enhanced autophagy. Multiple observational studies and meta-analyses suggest 20-40% reduced incidence of several cancers (colorectal, breast, prostate, pancreatic) in metformin users versus other antidiabetic therapies. Proposed mechanisms include AMPK-mediated mTOR inhibition and reduced circulating insulin/IGF-1 levels. Prospective clinical trials are ongoing. The UKPDS demonstrated a 39% reduction in myocardial infarction risk in overweight diabetic patients treated with metformin. Mechanisms include improved endothelial function, reduced oxidative stress, and anti-inflammatory effects independent of glucose lowering. Metformin is weight-neutral to mildly weight-reducing, unlike many other diabetes medications. Typical weight loss is 1-3 kg over 6-12 months. May reduce visceral fat preferentially. Often prescribed off-label for weight management in non-diabetic individuals with insulin resistance.